Mass Tort Advertising Campaign
Zantac (ranitidine) was one of the best-selling heartburn medications in history, manufactured and marketed by Sanofi, GSK, Pfizer, and Boehringer Ingelheim before a 2020 FDA market withdrawal. The core allegation is that ranitidine is an inherently unstable molecule that degrades into NDMA — a probable human carcinogen — and that long-term users were exposed to elevated cancer risk without adequate warning. The injuries at the center of this litigation are bladder cancer, stomach cancer, and esophageal cancer.
For plaintiff firms still actively building their Zantac dockets, paid social acquisition remains a viable channel. The MDL was dismissed at the federal level, but state-court litigation continues, and intake remains open. That combination — a household-name drug, a clear contamination narrative, and serious oncological injuries — creates the conditions for efficient claimant identification on Facebook and Instagram, provided campaigns are built around the right qualifying profile.
The federal Zantac MDL was dismissed, a development that reshaped — but did not end — the litigation landscape. State-court actions against Sanofi, GSK, Pfizer, and Boehringer Ingelheim are ongoing, and firms with well-documented claimant files continue to pursue individual and coordinated state-level claims. The injuries driving the strongest cases are bladder cancer, stomach cancer, and esophageal cancer, each tied to the NDMA-exposure theory that underpins the broader litigation.
Because ranitidine was available both by prescription and over the counter for decades, the potential claimant population is wide — but not every user presents an equally compelling case. Firms building or expanding their dockets need acquisition campaigns calibrated to surface the subset of former users whose exposure duration and cancer diagnosis align with the injuries courts and defendants are most focused on. That targeting precision is where a disciplined paid-social strategy earns its value.
Zantac's brand recognition is a genuine creative asset. Unlike obscure industrial chemicals or niche pharmaceuticals, ranitidine was a medicine millions of Americans kept in their medicine cabinets for years — often for chronic conditions requiring daily use. That familiarity means Meta audiences respond to direct, recognition-based creative: 'Did you take Zantac for a year or more before 2020?' is a question that stops the scroll for the right person. The creative challenge is pairing that recognition with the gravity of the associated cancers — bladder, stomach, and esophageal — in a way that is clear and compelling without being exploitative. Video and static formats that walk through the NDMA contamination story in plain language consistently outperform generic 'lawsuit alert' creative for this tort.
On the audience side, Meta's age and health-interest signals allow us to concentrate spend on users most likely to have been long-term antacid consumers — typically adults 45 and older with histories of GERD, acid reflux, or ulcer-related conditions. Lookalike modeling seeded from early intake conversions sharpens that targeting further over the life of a campaign. Intake flows for Zantac need to handle the MDL-dismissed context carefully: claimants will have questions about where their case goes, and a well-designed pre-qualification funnel that sets accurate expectations reduces drop-off and improves the quality of signed retainers delivered to the firm.
Mass Tort Ad Agency runs Zantac (Ranitidine) campaigns on the same transparent model as every tort: actual Meta ad spend at cost plus a flat 15% management fee, a one-time $1,000 setup fee per tort, and $100 per signed retainer for CloudIntake qualification. No per-case markups, no lead resale, and the firm owns its ad account, pixel, creative, and claimant data.
We build, run, and qualify Zantac (Ranitidine) claimant-acquisition campaigns end to end. Book a call and we'll walk you through the creative, audience, and intake plan.
Book a strategy call